Veracyte Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Veracyte hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	2.8%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$0.89
Erwartete Dividendenrendite in 3 Jahren	0%

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking

Jun 06

Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 09

Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S

Apr 18

A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)

Mar 18

Veracyte Percepta Genomic Sequencing Classifier demonstrates accuracy in lung cancer risk

Jul 13

Veracyte: Not A Healthy Diagnosis

May 12

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von VCYT in der Vergangenheit stabil geblieben ist.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von VCYT gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Veracyte Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von VCYT im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (VCYT)	n/a
Untere 25 % des Marktes (US)	1.6%
Markt Top 25 % (US)	4.8%
Branchendurchschnitt (Biotechs)	2.8%
Analystenprognose in 3 Jahren (VCYT)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von VCYT im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von VCYT im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von VCYT, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da VCYT keine Ausschüttungen gemeldet hat.

Veracyte Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking

Veracyte, Inc. Announces New Afirma Grid Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors

Consensus EPS estimates upgraded to US$0.052 loss

New major risk - Revenue and earnings growth

Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025

Veracyte, Inc. Raises Earnings Guidance for the Full-Year 2024

Veracyte, Inc., Annual General Meeting, Jun 12, 2024

Veracyte, Inc. to Report Q1, 2024 Results on May 07, 2024

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

New minor risk - Shareholder dilution

New minor risk - Profitability

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Veracyte, Inc. Provides Earnings Guidance for the Full Year 2024

Veracyte, Inc. Announces Retirement of John L. Bishop, A Member of the Board of Directors

Veracyte, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Veracyte, Inc. (NasdaqGM:VCYT) completed the acquisition of C2i Genomics, Inc.

Veracyte, Inc. (NasdaqGM:VCYT) has reached a definitive agreement to acquire C2i Genomics, Inc. for $95 million.

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

Veracyte, Inc. Reports Consolidated Impairment Charges for the Quarter Ended September 30, 2023

Veracyte, Inc. Raises Revenue Guidance for the Full Year 2023

Veracyte, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Veracyte, Inc. Announces New Data from A Large, Randomized Phase 3 Trial Reinforce the Value of the Decipher Prostate Genomic Classifier in Helping Physicians Make More Informed Treatment Decisions for Their Patients with Prostate Cancer

Veracyte, Inc. Announces New Data Presented At the 2023 American Thyroid Association Annual Meeting Demonstrate That Veracyte's Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer

Veracyte, Inc. Appoints Phillip G. Febbo as Chief Scientific Officer and Chief Medical Officer, Effective 2, 2023

Veracyte, Inc. Announces Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer

Consensus estimates of losses per share improve by 11%

Veracyte, Inc. Announces Resignation of Tina S. Nova as General Manager, Urological Cancers Effective September 4, 2023

Veracyte, Inc. Revises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Veracyte, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Veracyte, Inc. Announces New Data Suggest Veracyte's Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer

Independent Director notifies of intention to sell stock

Veracyte Announces That New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer

Veracyte, Inc. Raises Earnings Guidance for the Full-Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S

Co-Founder & Executive Chairwoman notifies of intention to sell stock

Co-Founder & Executive Chairwoman notifies of intention to sell stock

A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)

Independent Director notifies of intention to sell stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Veracyte, Inc. Announces New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment

Veracyte, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Co-Founder & Executive Chairwoman exercised options and sold US$682k worth of stock

Veracyte, Inc. Announces Resignation of Giulia C. Kennedy as Global Chief Scientific Officer and Chief Medical Officer

Co-Founder & Executive Chairwoman exercised options and sold US$1.4m worth of stock

Independent Director recently sold US$181k worth of stock

Consensus estimates of losses per share improve by 28%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Veracyte, Inc. Raises Revenue Guidance for the Year 2022

Veracyte, Inc. Announces New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy

Veracyte, Inc. Announces Data That Provide New Insights into Thyroid Tumor Behavior

New Data Presented At American College of Chest Physicians 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer

Co-Founder & Executive Chairwoman exercised options to buy US$188k worth of stock.

Veracyte, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Veracyte, Inc. Publishes New Data in JNCI Demonstrate its Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men

Veracyte, Inc. Names John Leite as Senior Vice President and General Manager of Pulmonology & Market Access

Veracyte, Inc. Announces That New Data from a Phase 3 Trial of the Multi-Center, Multi-National, Randomized Stampede Platform Protocol

Veracyte, Inc. Announces New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for Car T-Cell Therapy in Patients with Large B-Cell Lymphoma

Veracyte, Inc. Appoints Eliav Barr to Its Board of Directors

Co-Founder & Executive Chairwoman recently sold US$3.4m worth of stock

Consensus estimates of losses per share improve by 10%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Veracyte, Inc. Revises Revenue Guidance for the Year 2022

Consensus forecasts updated

Veracyte, Inc. Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid

Veracyte, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Veracyte, Inc. Announces New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte’s Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis

Veracyte Percepta Genomic Sequencing Classifier demonstrates accuracy in lung cancer risk

Veracyte, Inc. Shows Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice

CEO & Director recently bought US$980k worth of stock